Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
175results about "Melanocyte-stimulating hormone" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
C-aryl glucoside SGLT2 inhibitors and method
Owner:BRISTOL MYERS SQUIBB CO
Metallopeptide compositions for treatment of sexual dysfunction
Owner:PALATIN TECH INC
Activatable clostridial toxins
InactiveUS20080032931A1Minimize security riskEnhanced efficiency and rateHydrolasesPeptide/protein ingredientsClostridial toxinSaxitoxin
Owner:ALLERGAN INC
Bis-sulfhydryl macrocyclization systems
InactiveUS20090047711A1Good biological propertiesSimple structureApoptosis related proteinsCyclic peptide ingredientsCombinatorial chemistryAmino acid
The present invention provides novel peptidomimetic macrocycles and methods for their preparation and use, as well as amino acid analogs and macrocycle-forming linkers, and kits useful in their production.
Owner:AILERON THERAPEUTICS INC
Bis-Sulfhydryl Macrocyclization Systems
ActiveUS20090088553A1Good biological propertiesSimple structureCell receptors/surface-antigens/surface-determinantsPeptide preparation methodsCombinatorial chemistryAmino acid
The present invention provides novel peptidomimetic macrocycles and methods for their preparation and use, as well as amino acid analogs and macrocycle-forming linkers, and kits useful in their production.
Owner:AILERON THERAPEUTICS INC
Methods for treatment of headaches by administration of oxytocin
InactiveUS20070054843A1Reduction of pain ratingReduce probabilityOrganic active ingredientsNervous disorderHeadache DisordersTrigeminal neuralgia
The present invention relates to methods for the treatment of headache and headache disorders. The methods comprise administration of an oxytocin peptide for the treatment of primary and secondary headaches or trigeminal neuralgia.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV +2
Bis-sulfhydryl macrocyclization systems
ActiveUS20100184628A1Good biological propertiesSimple structureApoptosis related proteinsCyclic peptide ingredientsCombinatorial chemistryAmino acid
Owner:AILERON THERAPEUTICS INC
Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
The present invention relates to methods for prevention and treatment of bone-related or nutrition-related disorders using a GLP molecule or GLP activator either alone or in combination with another therapeutic. The present invention also encompasses methods of diagnosing or monitoring the progression of a disorder. The invention also encompasses methods of monitoring the effectiveness of treatment of the invention.
Owner:SANOS BIOSCI
Methods for treating drug addiction
This invention describes gene targets for the development of therapeutics to treat drug addiction. Animal models of drug craving and relapse have been developed and used to find gene expression changes in key brain regions implicated in cocaine addiction. The genes whose expression levels are altered serve as pharmacological targets with the purpose of preventing or inhibiting cocaine craving and relapse in human cocaine addicts.
Owner:IRM
Peptides for use in treating obesity
Novel cyclic and linear peptides of the formula R1—X—X1—X2—X3—X4—X5—X6—X7—X8—X9—X10—X11—R2 are useful in the treatment of obesity are provided.
Owner:NOVO NORDISK AS
Intermedin analogue prepared by bonding ring core sequence with biotin or cell-penetrating peptides
The invention relates to an intermedin analogue prepared by bonding a ring core sequence with biotin or cell-penetrating peptides and a preparation method and application of the intermedin analogue. The intermedin analogue is prepared by bonding a functional unit with the biotin or a load unit; the functional unit is a seven-peptide structure formed by connecting the ring core sequence c (Asp-Dab-D-Phe-Arg-Trp-Lys) with a connection unit Arg, the structure is Arg-c (Asp-Dab-D-Phe-Arg-Trp-Lys); the load unit is the 48th-57th peptide segments Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg or the 55th-57th peptide segments Arg-Arg-Arg in the 47th-60th segments of HIV (human immunodeficiency virus)-1TAT protein. The intermedin analogue disclosed by the invention can penetrate through mucosa or skin to be absorbed, and can be applied to treatment of diseases such as male and female sexual dysfunction, obesity, pigmentation deficiency and the like.
Owner:张嘎
Modified alpha-MSH peptides and derivatives thereof
InactiveUS20050130901A1High activityReduce productionPeptide/protein ingredientsImmunoglobulinsMicroorganismMechanism of action
Novel peptides with antimicrobial activity are disclosed. The novel peptides are octomeric peptides modified from alpha-MSH. The modified alpha-MSH antimicrobial peptides disclosed herein may have enhanced activity against microbes over alpha-MSH due to modifications in peptide sequence and chirality of amino acids. Due an identified mechanism of action for antimicrobial activity in which cAMP accumulates in the microbial cell, it may be that microbes will not generate resistance to these modified alpha-MSH antimicrobial peptides.
Owner:ZENGEN
Melanocortin 1 receptor selective compounds
A compound of general formula (1) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are H or methyl, R13, R14, R15 and R16 are H or alkyl, wherein L1 and L2 are linkers selected from single bond, methyl, ethyl, wherein R19, R20 and R21 are H or —CH2X, NT is selected from H, hydroxyl, alkyl, aminoacid, aminoacid analogue, polypeptide and functional group, CT is selected from hydrogen, hydroxyl, alkyl, aminoacid, aminoacid analogue, polypeptide and functional group shows high selectivity and high affinity for MC1-receptors in combination with effective stimulation or inhibiton of cAMP formation in MC1-receptor expressing cells but low affinity for other subtypes of MC-receptors and may be used to treat a wide range of inflammatory conditions. Also disclosed is a DNA molecule and a corresponding vector encoding the compound, a fusion protein comprising a copy of it, a vector comprising DNA encoding the fusion protein, and a pharmaceutical composition comprising the compound.
Owner:ACTION PHARM AS
Novel Melanocortin Receptor Agonists
Small cyclic peptides of the formula X1-X2-X3-X4-X5-X6-X7-R1 comprising 7-12 amino acid residues are provided. Said peptides are MC4 receptor agonists, and thus useful in the treatment of obesity and related diseases.
Owner:NOVO NORDISK AS
Use of melanin for inhibition of angiogenesis and macular degeneration
InactiveUS20020128304A1Strong anti-macular degeneration activityHigh activityBiocideSenses disorderDiseaseAngiogenesis growth factor
Composition and methods of using melanin, or melanin-promoting compounds, for inhibiting angiogenesis to treat angiogenesis-dependent diseases, such as macular degeneration and cancer.
Owner:CHILDRENS MEDICAL CENT CORP
Melanocortin receptor binding mimetibodies, compositions, methods and uses
InactiveUS20060105951A1Peptide/protein ingredientsAntibody mimetics/scaffoldsNucleotidePolynucleotide
Melanocortin receptor binding mimetibody polypeptides are disclosed. Polynucleotides encoding these polypeptides, cells comprising these polynucleotides or expressing the mimetibodies, and methods of making and using the forgoing are also disclosed.
Owner:CUNNINGHAM MARK +4
Nitrogen-containing heterocyclic compounds and methods of use thereof
Owner:MERCK SHARP & DOHME LLC
Bis-sulfhydryl macrocyclization systems
InactiveUS7981998B2Good biological propertiesSimple structureCell receptors/surface-antigens/surface-determinantsPeptide preparation methodsCombinatorial chemistryAmino acid
Peptidomimetic macrocycles and methods for their preparation and use, as well as amino acid analogs and macrocycle-forming linkers, and kits useful in their production, are provided.
Owner:AILERON THERAPEUTICS INC
Novel Peptides for Use in the Treatment of Obesity
The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.
Owner:NOVO NORDISK AS
Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity
InactiveUS20050239711A1Prevent obesityReduce intakePeptide/protein ingredientsMetabolism disorderMC4 ReceptorMelanocortin receptor activity
Peptides of formulae I, II and III that selectively activate melanocortin-4 (MC-4) receptor activity.
Owner:CHEN LI +5
Multiple agent therapy for sexual dysfunction
InactiveUS20050222014A1Improve reliabilityIncreased temporal durationBiocideHeavy metal active ingredientsSexual dysfunctionAgonist
Multiple agent therapy for treatment of sexual dysfunction, including male erectile dysfunction, with sequential administration a type V phosphodiesterase inhibitor (PDE-5), such as sildenafil, preferably wherein the PDE-5 inhibitor is administered by oral dose means, and a melanocortin 3 and / or 4 receptor agonist, such as Ac-Nle-cyclo(-Asp-His-D-Phe-Arg-Trp-Lys)-OH (PT-141) preferably wherein the PT-141 is formulated for and administered by intranasal means, and further preferably wherein the PDE-5 inhibitor is administered prior to PT-141.
Owner:PALATIN TECH INC
Therapeutically active alpha msh analogues
InactiveUS20090069242A1Increases maximal efficacyGood anti-inflammatory effectSenses disorderNervous disorderMelanocyteMelanocyte-stimulating hormone
The invention describes peptide analogues of a-melanocyte-stimulating hormone (a-MSH), which posses an increased efficacy compared to the native α-MSH peptide. The α-MSH analogues exhibit increased anti-inflammatory effects and increased capability to prevent ischemic conditions compared to α-MSH. The invention further discloses use of the peptides for the manufacture of pharmaceutical compositions for the treatment or prophylaxis of a condition in the tissue of one or more organs of a mammal, and moreover pharmaceutical compositions.
Owner:ABBVIE INC
Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
InactiveUS20040052862A1Less stringentIncrease stringencyBiocideHeavy metal active ingredientsDiseaseMedicine
The present invention relates to methods for prevention and treatment of bone-related or nutrition-related disorders using a GLP molecule or GLP activator either alone or in combination with another therapeutic. The present invention also encompasses methods of diagnosing or monitoring the progression of a disorder. The invention also encompasses methods of monitoring the effectiveness of treatment of the invention.
Owner:SANOS BIOSCI
Treatment of anorexia nervosa and bulimia
InactiveUS20020187932A1Significantly enrichedReduce signalingNervous disorderPeptide/protein ingredientsPharmacologyAN - Anorexia nervosa
According to the present invention, a method for the treatment of anoxeria nervosa (AN) or bulimia comprises administering to a patient having AN or bulimia an effective amount of an inverse agonist on MC4-r.
Owner:ELAN DRUG DELIVERY LTD
In situ langerhans cell vaccine
A method for entrapping migratory antigen presenting cells (APCs) and particularly Langerhans cells (LCs,) in vivo is provided. The method entails creating an artificial gradient of APC-attracting chemotactic factor in the homing path of APCs in vivo. Also provided is a composition for entrapping APCs and particularly, migratory LCs. In addition, a method for loading APCs in situ with antigen is provided. The method comprises entrapping APCs in vivo and subsequently loading the APCs in situ with antigen. Correspondingly, a composition for loading APCs in situ is also provided. Further provided is a method for stimulating the migration of entrapped APCs to draining lymph nodes. The ability to stimulate the migration of entrapped APCs to draining lymph nodes is useful, inter alia, for regulating an immune response in a subject. In addition, an in situ APC-based vaccine is provided which does not require any time-consuming, costly ex vivo manipulations.
Owner:US SOUTHWESTERN MEDICAL CENT
Multiple agent therapy for sexual dysfunction
Owner:PALATIN TECH INC
Methods for treatment of pain
The invention provides for methods and compositions for treatment of pain via craniofacial mucosal administration of an analgesic compound (e.g. a non-opioid analgesic peptide, an NOP agonist or N / OFQ). Intranasal administration of certain analgesic peptides such as N / OFQ results in global analgesic effects.
Owner:TONIX PHARMA HLDG LTD
Peptides for use in treating obesity
Novel cyclic and linear peptides of the formula R1—X—X1—X2—X3—X4—X5—X6—X7—X8—X9—X10—X11—R2 are useful in the treatment of obesity are provided.
Owner:NOVO NORDISK AS
Intranasal administration of active agents to the central nervous system
A method for delivering a polypeptide to the central nervous system of a mammal is provided. The method involves attaching the polypeptide to an antibody or an antibody fragment and administering the fusion polypeptide intranasally, for delivery to the central nervous system. Methods of treatment are also provided, where a therapeutically effective amount of the composition is delivered to the nasal cavity of a mammal.
Owner:ALZA CORP
Bifunctional hormone and uses thereof
InactiveUS20090011997A1Antibody mimetics/scaffoldsTetrapeptide ingredientsDiseaseHormones regulation
A bifunctional hormone exhibiting an alpha-MSH activity and a natriuretic peptide activity is described. The bifunctional hormone comprises for example a first domain having alpha-MSH related hormonal activity covalently linked to a second domain having natriuretic peptide related hormonal activity. The bifunctional hormone of the present invention is useful for example for the prevention and / or treatment of renal related diseases or conditions, such as acute renal failure (ARF) or acute kidney injury (AKI).
Owner:THERATECHONOLGIES INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com